[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1113985T1 - Μεθοδοι παραγωγης κυκλοαλκυλκαρβοξυαμιδο-πυριδινο βενζοϊκων οξεων - Google Patents

Μεθοδοι παραγωγης κυκλοαλκυλκαρβοξυαμιδο-πυριδινο βενζοϊκων οξεων

Info

Publication number
CY1113985T1
CY1113985T1 CY20131100380T CY131100380T CY1113985T1 CY 1113985 T1 CY1113985 T1 CY 1113985T1 CY 20131100380 T CY20131100380 T CY 20131100380T CY 131100380 T CY131100380 T CY 131100380T CY 1113985 T1 CY1113985 T1 CY 1113985T1
Authority
CY
Cyprus
Prior art keywords
acid
cyclocylcarvoxymide
pyridene
production
methods
Prior art date
Application number
CY20131100380T
Other languages
English (en)
Inventor
David Siesel
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of CY1113985T1 publication Critical patent/CY1113985T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε μια μέθοδο παροχής του 3-(6-(1-(2,2-διφθοροβενο[d][1,3]διοξολ-5-υλ)κυκλοπροπανο-καρβοξαμιδο-3-μεθυλπυριδιν-2-υλ)βενζοϊκού οξέος σε ουσιαστικώς ελεύθερη μορφή (Ένωση 1).
CY20131100380T 2007-12-07 2013-05-13 Μεθοδοι παραγωγης κυκλοαλκυλκαρβοξυαμιδο-πυριδινο βενζοϊκων οξεων CY1113985T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1218107P 2007-12-07 2007-12-07
US10957308P 2008-10-30 2008-10-30
EP08859582A EP2231606B1 (en) 2007-12-07 2008-12-04 Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids

Publications (1)

Publication Number Publication Date
CY1113985T1 true CY1113985T1 (el) 2016-07-27

Family

ID=40329178

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20131100380T CY1113985T1 (el) 2007-12-07 2013-05-13 Μεθοδοι παραγωγης κυκλοαλκυλκαρβοξυαμιδο-πυριδινο βενζοϊκων οξεων
CY20161101202T CY1118332T1 (el) 2007-12-07 2016-11-22 Μεθοδοι παραγωγης κυκλοαλκυλκαρβοξamιδο-πυριδιno βενζοϊκων οξεων
CY20161101240T CY1118310T1 (el) 2007-12-07 2016-11-30 Μεθοδοι παραγωγης κυκλοαλκυλκαρβοξυαμιδο-πυριδινο βενζοϊκων οξεων
CY20171100629T CY1118992T1 (el) 2007-12-07 2017-06-15 Μεθοδοι παραγωγης κυκλοαλκυλκαρβοξαμιδο-πυριδινο βενζοϊκων οξεων

Family Applications After (3)

Application Number Title Priority Date Filing Date
CY20161101202T CY1118332T1 (el) 2007-12-07 2016-11-22 Μεθοδοι παραγωγης κυκλοαλκυλκαρβοξamιδο-πυριδιno βενζοϊκων οξεων
CY20161101240T CY1118310T1 (el) 2007-12-07 2016-11-30 Μεθοδοι παραγωγης κυκλοαλκυλκαρβοξυαμιδο-πυριδινο βενζοϊκων οξεων
CY20171100629T CY1118992T1 (el) 2007-12-07 2017-06-15 Μεθοδοι παραγωγης κυκλοαλκυλκαρβοξαμιδο-πυριδινο βενζοϊκων οξεων

Country Status (26)

Country Link
US (4) US8124781B2 (el)
EP (4) EP2639223B1 (el)
JP (4) JP5702149B2 (el)
KR (3) KR101612009B1 (el)
CN (2) CN101910134B (el)
AU (1) AU2008335440B2 (el)
BR (1) BRPI0820902A2 (el)
CA (3) CA3147290A1 (el)
CL (1) CL2010000631A1 (el)
CY (4) CY1113985T1 (el)
DK (4) DK2231606T3 (el)
EA (1) EA201070700A1 (el)
ES (4) ES2604555T3 (el)
HK (2) HK1146820A1 (el)
HR (4) HRP20130418T1 (el)
HU (3) HUE031871T2 (el)
IL (4) IL206205A (el)
LT (3) LT2639223T (el)
MX (4) MX2010006183A (el)
NZ (3) NZ585794A (el)
PL (4) PL2231606T3 (el)
PT (4) PT2639223T (el)
RS (4) RS55360B1 (el)
SI (4) SI2231606T1 (el)
WO (1) WO2009076142A2 (el)
ZA (1) ZA201003624B (el)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EP1664006A2 (en) 2003-09-06 2006-06-07 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
NZ547220A (en) * 2003-11-14 2009-12-24 Vertex Pharma Thiazoles and oxazoles useful as modulators of ATP-binding cassette transporters
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
DK2489659T3 (en) 2004-06-24 2018-02-12 Vertex Pharma Modulators of ATP binding cassette conveyors
KR20080053297A (ko) 2005-08-11 2008-06-12 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유종 트랜스막 전도도 조정자의 조절자
CA2627358C (en) 2005-11-08 2015-10-06 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
WO2007087066A2 (en) 2005-12-28 2007-08-02 Vertex Pharmaceuticals Incorporated 1-(benzo [d] [1,3] di0x0l-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
PT3091011T (pt) 2006-04-07 2018-03-07 Vertex Pharma Moduladores de transportadores de cassete de ligação a atp
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
AU2008251504B2 (en) 2007-05-09 2013-07-18 Vertex Pharmaceuticals Incorporated Modulators of CFTR
EP2158183A2 (en) * 2007-05-25 2010-03-03 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
WO2009038913A2 (en) 2007-08-24 2009-03-26 Vertex Pharmaceuticals Incorporated Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
SI2217572T1 (sl) * 2007-11-16 2014-05-30 Vertex Pharmaceuticals Incorporated Izokinolinski modulatorji prenaĺ alcev z atp-vezavno kaseto
JP2011506331A (ja) * 2007-12-07 2011-03-03 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の処方物
US20100036130A1 (en) * 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
PL2225230T3 (pl) 2007-12-07 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
PL2231606T3 (pl) 2007-12-07 2013-07-31 Vertex Pharma Sposoby wytwarzania kwasów cykloalkilokarboksyamidopirydynobenzoesowych
WO2009108657A2 (en) 2008-02-28 2009-09-03 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
ES2442945T3 (es) * 2008-03-31 2014-02-14 Vertex Pharmaceuticals Inc. Derivados de piridilo como moduladores del CFTR
MX2011003249A (es) 2008-09-29 2011-05-19 Vertex Pharma Unidades de dosificacion del acido 3-(6-(1-(2,2-difluorobenzo[d][1 ,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoi co.
AR074060A1 (es) 2008-10-23 2010-12-22 Vertex Pharma Moduladores del regulador de conductancia transmembrana de la fibrosis quistica
SG193156A1 (en) 2009-03-20 2013-09-30 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
DK2555754T3 (en) * 2010-04-07 2016-04-18 Vertex Pharma Solid forms of 3- (6- (1- (2,2-difluoro-benzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) -benzoic acid
AU2011237601B2 (en) 2010-04-07 2015-08-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
ES2608474T3 (es) 2010-04-22 2017-04-11 Vertex Pharmaceuticals Incorporated Proceso de producción de compuestos indol cycloalkylcarboxamido
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US9254291B2 (en) 2011-11-08 2016-02-09 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20130224293A1 (en) 2012-02-27 2013-08-29 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2872122A1 (en) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
BR112015023328A2 (pt) 2013-03-13 2017-07-18 Flatley Discovery Lab compostos de piridazinona e métodos para o tratamento de fibrose cística
NZ720958A (en) 2013-11-12 2022-02-25 Vertex Pharma Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
LT3131582T (lt) 2014-04-15 2018-10-25 Vertex Pharmaceuticals Incorporated Farmacinės kompozicijos, skirtos cistinės fibrozės transmembraninio laidumo reguliatorių sukeltų ligų gydymui
GB201415381D0 (en) 2014-08-29 2014-10-15 Algipharma As Inhalable powder formulations of alginate oligomers
RU2020134082A (ru) 2014-10-06 2020-11-27 Вертекс Фармасьютикалз Инкорпорейтед Модуляторы регулятора трансмембранной проводимости при муковисцидозе
MX370450B (es) 2014-10-07 2019-12-13 Vertex Pharma Co-cristales de moduladores de regulador de conductancia de transmembrana en fibrosis quistica.
AU2015350049B2 (en) 2014-11-18 2021-08-19 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography
GB201504878D0 (en) 2015-03-23 2015-05-06 Algipharma As Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
WO2016196303A1 (en) * 2015-05-29 2016-12-08 Emory University 3-(phenyl)-n-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of cftr protein mediated diseases
WO2016196297A1 (en) * 2015-05-29 2016-12-08 Emory University 2-amino-n'-benzylideneacetohydrazides and derivatives for the management of cftr protein mediated diseases
WO2017017696A1 (en) * 2015-07-27 2017-02-02 Mylan Laboratories Limited Process for the preparation of lumacaftor
CN105130949B (zh) * 2015-09-02 2019-01-29 阜新奥瑞凯新材料有限公司 1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙基腈的制备方法
WO2017056109A2 (en) 2015-09-29 2017-04-06 Mylan Laboratories Limited Novel forms of lumacaftor and processes for the preparation thereof
GB201517639D0 (en) 2015-10-06 2015-11-18 Algipharma As Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
CN107033120B (zh) * 2016-02-03 2020-03-17 苏州旺山旺水生物医药有限公司 2-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)乙氰的制备方法
WO2017137900A1 (en) 2016-02-10 2017-08-17 Lupin Limited Amorphous lumacaftor and its solid dispersion
MX2019003620A (es) 2016-09-30 2019-08-01 Vertex Pharma Modulador del regulador de conductancia transmembrana de fibrosis quistica, composiciones farmaceuticas, metodos de tratamiento y proceso para producir el modulador.
WO2018107040A1 (en) * 2016-12-09 2018-06-14 Vertex Pharmaceuticals Incorporated 1-(2-fluorophenyl)-n-[1-(2-fluoro-4-pyridyl)pyrazol-3-yl]cyclopropanecarboxamide, its solid forms and pharmaceutical uses thereof
PT3551622T (pt) 2016-12-09 2020-11-12 Vertex Pharma Modulador do regulador da condutância transmembrana da fibrose quística, composições farmacêuticas, métodos de tratamento e processo de fabrico do modulador
WO2018107056A1 (en) * 2016-12-09 2018-06-14 Vertex Pharmaceuticals Incorporated 1,3-substitued pyrazole compounds useful for reduction of very long chain fatty acic levels
BR112019025801A2 (pt) 2017-06-08 2020-07-07 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
US11517564B2 (en) 2017-07-17 2022-12-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
MX2020001302A (es) 2017-08-02 2020-03-20 Vertex Pharma Procesos para preparar compuestos de pirrolidina.
IL273831B2 (en) 2017-10-19 2024-10-01 Vertex Pharma Crystal forms and preparations of CFTR modulators
JP7245834B2 (ja) 2017-12-08 2023-03-24 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを作成するためのプロセス
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
PL3752510T3 (pl) 2018-02-15 2023-05-08 Vertex Pharmaceuticals Incorporated Makrocykle jako modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa, ich kompozycje farmaceutyczne, ich zastosowanie w leczeniu mukowiscydozy oraz proces ich wytwarzania
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2020214921A1 (en) 2019-04-17 2020-10-22 Vertex Pharmaceuticals Incorporated Solid forms of modulators of cftr
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
US20220313698A1 (en) 2019-08-14 2022-10-06 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AU2020328028A1 (en) 2019-08-14 2022-03-17 Vertex Pharmaceuticals Incorporated Crystalline forms of CFTR modulators
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US20230382924A1 (en) 2020-10-07 2023-11-30 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076620A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CA3197173A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CA3197857A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225737A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076626A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225748A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225762A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225765A2 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225750A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2023150236A1 (en) 2022-02-03 2023-08-10 Vertex Pharmaceuticals Incorporated Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol
KR20240144973A (ko) 2022-02-03 2024-10-04 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 치료 방법
WO2023154291A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
IL315715A (en) 2022-04-06 2024-11-01 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulation
WO2023224924A1 (en) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Solid forms of a macrocyclic compounds as cftr modulators and their preparation
AU2023273614A1 (en) 2022-05-16 2024-11-07 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis

Family Cites Families (213)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3758475A (en) * 1971-07-20 1973-09-11 Sandoz Ag Pyrido(2,3-d)pyrimidin 2 ones
IT1226048B (it) 1981-12-14 1990-12-10 Medea Res Srl Composti ad attivita'antiinfiammatoria, processo per la loro preparazione e composizioni farmaceutiche relative
EP0081756B1 (en) 1981-12-14 1985-05-15 MEDEA RESEARCH S.r.l. New compounds with antiinflammatory and antitussive activity, process for their preparation and relative pharmaceutical compositions
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US5981714A (en) 1990-03-05 1999-11-09 Genzyme Corporation Antibodies specific for cystic fibrosis transmembrane conductance regulator and uses therefor
JP3167762B2 (ja) * 1990-11-27 2001-05-21 武田薬品工業株式会社 ピリドピリダジン誘導体およびその用途
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
CA2107196A1 (en) 1992-09-29 1994-03-30 Mitsubishi Chemical Corporation Carboxamide derivatives
GB9317764D0 (en) 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
US5854234A (en) * 1993-10-21 1998-12-29 G. D. Searle & Co. Amidino dervatives useful as nitric oxide synthase inhibitors
DE4405712A1 (de) * 1994-02-23 1995-08-24 Basf Ag Substituierte Naphthyridine und deren Verwendung
IL113313A (en) * 1994-04-11 1999-09-22 Sankyo Co Heterocyclic compounds and pharmaceutical compositions containing the same
PL182502B1 (pl) 1994-09-27 2002-01-31 Janssen Pharmaceutica Nv Nowe związki, pochodne bicyklicznego benzoesanu N-podstawionego piperydynylu, środek farmaceutyczny i sposób wytwarzania pochodnych bicyklicznego benzoesanu N-podstawionego piperydynylu
US5656256A (en) 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5510379A (en) 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
WO1997036871A1 (en) * 1996-03-29 1997-10-09 Pfizer Inc. 6-phenylpyridyl-2-amine derivatives
EP0891334A1 (en) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
PT984778E (pt) 1996-08-23 2002-09-30 Agouron Pharma Ligandos do neuropeptido y
CA2276081A1 (en) 1996-12-30 1998-07-09 Lekhanh O. Tran Inhibitors of farnesyl-protein transferase
US5948814A (en) 1997-02-20 1999-09-07 The Curators Of The University Of Missouri Genistein for the treatment of cystic fibrosis
WO1998047868A1 (en) 1997-04-18 1998-10-29 Smithkline Beecham Plc Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
ID24376A (id) * 1997-10-02 2000-07-13 Sankyo Co Turunan-turunan asam amidokarboksilat
JP2003517266A (ja) 1998-02-17 2003-05-27 ジー・ディー・サール・アンド・カンパニー ラクタムの酵素分割方法
AU4317899A (en) 1998-06-08 1999-12-30 Schering Corporation Neuropeptide y5 receptor antagonists
US6426331B1 (en) 1998-07-08 2002-07-30 Tularik Inc. Inhibitors of STAT function
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
DE69926806D1 (de) 1998-12-18 2005-09-22 Bristol Myers Squibb Pharma Co N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
TR200102489T2 (tr) 1999-02-24 2002-04-22 F.Hoffmann-La Roche Ag 3-Fenilpiridin Türevleri ve bunların NK-1 alıcı antagonistler olarak kullanılması
EP1157006B1 (en) 1999-02-24 2006-10-25 F. Hoffmann-La Roche Ag Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists
ATE496032T1 (de) 1999-02-24 2011-02-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
JP2003502408A (ja) 1999-06-18 2003-01-21 バイエル アクチェンゲゼルシャフト フェノキシフルオロピリミジン類
UA74539C2 (en) 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
WO2001046165A2 (en) 1999-12-16 2001-06-28 Novartis Ag N-heteroaryl-amides and their use as parasiticides
SK9742002A3 (en) 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
WO2001054690A1 (en) 2000-01-28 2001-08-02 Biogen, Inc. Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses
US20020065303A1 (en) 2000-02-01 2002-05-30 Bing-Yan Zhu Bivalent phenylene inhibitors of factor Xa
WO2001081317A1 (en) 2000-04-26 2001-11-01 Gliatech, Inc. Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives
AU2000249828A1 (en) 2000-05-03 2001-11-12 Taisho Pharmaceutical Co. Ltd. Stat4 and stat6 binding dipeptide derivatives
CA2379445C (en) 2000-06-01 2007-08-21 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of a.beta. protein production
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
NZ525014A (en) * 2000-09-15 2005-09-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
JP4272338B2 (ja) * 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
AU2002211379A1 (en) 2000-10-04 2002-04-15 The Children's Hospital Of Philadelphia Compositions and methods for treatment of cystic fibrosis
GB2367816A (en) 2000-10-09 2002-04-17 Bayer Ag Urea- and thiourea-containing derivatives of beta-amino acids
ATE269856T1 (de) 2000-10-20 2004-07-15 Merck Patent Gmbh Chirale binaphtol-verbindungen
US6884782B2 (en) 2000-11-08 2005-04-26 Amgen Inc. STAT modulators
JP4323802B2 (ja) * 2000-12-01 2009-09-02 エムジーアイ・ジーピー・インコーポレーテッド 化合物およびその使用
JP2002197001A (ja) 2000-12-27 2002-07-12 Fujitsu Ltd クライアント・サーバ型のシステムにおける情報の通信方法
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
CA2442654A1 (en) 2001-04-10 2002-10-10 Transtech Pharma, Inc. Probes, systems, and methods for drug discovery
EP1385577B1 (en) 2001-04-23 2006-04-19 F. Hoffman-la Roche AG Use of nk-1 receptor antagonists against benign prostatic hyperplasia
KR20040015716A (ko) * 2001-05-22 2004-02-19 뉴로젠 코포레이션 Ｃｒｆ1 조절자로서의 5-치환된-2-아릴피리딘
JP2003015528A (ja) 2001-06-28 2003-01-17 Mint Bureau Ministry Of Finance 画像表示構造
US20030083345A1 (en) 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
WO2003007888A2 (en) 2001-07-20 2003-01-30 Adipogenix, Inc. Fat accumulation-modulating compounds
JP4558314B2 (ja) 2001-07-20 2010-10-06 ベーリンガー インゲルハイム （カナダ） リミテッド ウイルスポリメラーゼインヒビター
US7427623B2 (en) 2001-09-11 2008-09-23 Smithkline Beecham Corporation 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
JP2003155285A (ja) 2001-11-19 2003-05-27 Toray Ind Inc 環状含窒素誘導体
JP2003221386A (ja) * 2001-11-26 2003-08-05 Takeda Chem Ind Ltd 二環性誘導体、その製造法およびその用途
CN100506807C (zh) 2001-12-21 2009-07-01 诺沃挪第克公司 作为gk活化剂的酰胺衍生物
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
FR2840807B1 (fr) 2002-06-12 2005-03-11 Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide
GB0221443D0 (en) * 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
US20050215614A1 (en) 2002-10-15 2005-09-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
WO2004041163A2 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity
JP2006512338A (ja) * 2002-12-12 2006-04-13 ファルマシア・コーポレーション マイトジェン活性化プロテインキナーゼ−活性化プロテインキナーゼ−２阻害剤としてのアミノシアノピリジンの使用法
ES2362656T3 (es) 2003-01-06 2011-07-11 Eli Lilly And Company Arilciclopropilacetamidas sustituidas como activadores de glucoquinasa.
RU2351590C2 (ru) * 2003-02-10 2009-04-10 Вертекс Фармасьютикалз Инкорпорейтед Способ получения диариламина
EP1601657A1 (en) 2003-03-12 2005-12-07 Vertex Pharmaceuticals Incorporated Pyrazole modulators of atp-binding cassette transporters
JP2006525329A (ja) 2003-04-30 2006-11-09 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 置換カルボン酸類
WO2004111014A1 (en) 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
CA2530075C (en) 2003-06-27 2012-08-21 Harvey Pollard Amphiphilic pyridinium compounds, method of making and use thereof
JP2005053902A (ja) * 2003-07-18 2005-03-03 Nippon Nohyaku Co Ltd フェニルピリジン類、その中間体及びこれを有効成分とする除草剤
CA2537829A1 (en) * 2003-09-05 2005-03-17 Neurogen Corporation Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands
EP1664006A2 (en) 2003-09-06 2006-06-07 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
WO2005035514A2 (en) 2003-10-08 2005-04-21 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups
FR2861304B1 (fr) * 2003-10-23 2008-07-18 Univ Grenoble 1 Modulateurs des canaux cftr
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
NZ547220A (en) 2003-11-14 2009-12-24 Vertex Pharma Thiazoles and oxazoles useful as modulators of ATP-binding cassette transporters
WO2005049034A2 (en) 2003-11-19 2005-06-02 Glaxo Group Limited Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders
MXPA06008606A (es) * 2004-01-30 2007-04-13 Vertex Pharma Moduladores de transportadores con casete de union a atp.
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
CA2555409A1 (en) * 2004-02-19 2005-09-01 Banyu Pharmaceutical Co., Ltd. Novel sulfone amide derivative
ES2241496B1 (es) * 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
US20080015196A1 (en) * 2004-04-16 2008-01-17 Neurogen Corporation Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands
US7585885B2 (en) * 2004-04-22 2009-09-08 Eli Lilly And Company Pyrrolidine derivatives useful as BACE inhibitors
JP2007533740A (ja) * 2004-04-22 2007-11-22 イーライ リリー アンド カンパニー Ｂａｃｅ阻害剤としてのアミド
WO2005117514A2 (en) 2004-06-01 2005-12-15 Tm Bioscience Corporation Method of detecting cystic fibrosis associated mutations
US20140343098A1 (en) 2004-06-24 2014-11-20 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
DK2489659T3 (en) 2004-06-24 2018-02-12 Vertex Pharma Modulators of ATP binding cassette conveyors
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CA2572549A1 (en) 2004-07-01 2006-01-12 Warner-Lambert Company Llc Preparation of pharmaceutical compositions containing nanoparticles
JP2008505124A (ja) 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
ZA200700811B (en) 2004-08-06 2008-10-29 Otsuka Pharma Co Ltd Aromatic compound
WO2006037117A1 (en) * 2004-09-27 2006-04-06 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP1802591B1 (en) 2004-10-12 2012-01-11 AstraZeneca AB Quinazoline derivatives
WO2006051394A1 (en) * 2004-11-15 2006-05-18 Pfizer Products Inc. Azabenzoxazoles for the treatment of cns disorders
KR101291483B1 (ko) 2004-12-15 2013-07-30 돔페 파르마 에스.피.에이. 2-아릴프로피온산 유도체 및 이들을 함유하는 제약학적조성물
JP4790260B2 (ja) * 2004-12-22 2011-10-12 出光興産株式会社 アントラセン誘導体を用いた有機エレクトロルミネッセンス素子
JP2008528580A (ja) 2005-01-27 2008-07-31 アストラゼネカ・アクチエボラーグ Ｐ２ｘ７受容体の阻害剤である新規二環式芳香族化合物
US7888374B2 (en) * 2005-01-28 2011-02-15 Abbott Laboratories Inhibitors of c-jun N-terminal kinases
JPWO2006082952A1 (ja) * 2005-02-01 2008-06-26 武田薬品工業株式会社 アミド化合物
EP1865949B1 (en) 2005-03-11 2012-11-14 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
EP1710246A1 (en) 2005-04-08 2006-10-11 Schering Aktiengesellschaft Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
EP1871762A2 (en) * 2005-04-18 2008-01-02 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
MX2007013049A (es) 2005-04-19 2008-01-11 Bayer Pharmaceuticals Corp Preparacion y uso de derivados de aril alquil acido para el tratamiento de la obesidad.
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
US8822451B2 (en) 2005-05-24 2014-09-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8017635B2 (en) 2005-06-02 2011-09-13 Fmc Corporation Phenylalkyl substituted heteroaryl derivatives
EP1919875A2 (en) 2005-06-21 2008-05-14 Astex Therapeutics Limited Pyrazole derivatives and their use as pka and pkb modulators
KR20080053297A (ko) 2005-08-11 2008-06-12 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유종 트랜스막 전도도 조정자의 조절자
ZA200802172B (en) 2005-08-11 2009-06-24 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
NZ565983A (en) 2005-09-09 2011-04-29 Smithkline Beecham Corp Pyridine derivatives and their use in the treatment of psychotic disorders
ATE453384T1 (de) 2005-09-23 2010-01-15 Hoffmann La Roche Neue dosierformulierung
JP2009511494A (ja) 2005-10-06 2009-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセットトランスポーターのモジュレーター
PL1940821T3 (pl) 2005-10-19 2013-08-30 Gruenenthal Gmbh Nowe ligandy receptora waniloidowego i ich zastosowanie do wytwarzania leków
CA2627358C (en) 2005-11-08 2015-10-06 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
US20120232059A1 (en) 2005-11-08 2012-09-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette Transporters
WO2007054480A1 (en) * 2005-11-08 2007-05-18 N.V. Organon 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
JP5103403B2 (ja) 2005-12-05 2012-12-19 スミスクライン ビーチャム コーポレーション ２−ピリミジニルピラゾロピリジンＥｒｂＢキナーゼ阻害剤
EP1968568A4 (en) * 2005-12-22 2011-04-13 Glaxosmithkline Llc HEMMER OF NUTS ACTIVITY
AU2006331614A1 (en) 2005-12-24 2007-07-05 Vertex Pharmaceuticals Incorporated Quinolin- 4 - one derivatives as modulators of ABC transporters
AU2006331565A1 (en) 2005-12-27 2007-07-05 Vertex Pharmaceuticals Incorporated Compounds useful in CFTR assays and methods therewith
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
WO2007087066A2 (en) 2005-12-28 2007-08-02 Vertex Pharmaceuticals Incorporated 1-(benzo [d] [1,3] di0x0l-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
PT3091011T (pt) 2006-04-07 2018-03-07 Vertex Pharma Moduladores de transportadores de cassete de ligação a atp
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
JP2009536969A (ja) 2006-05-12 2009-10-22 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミド組成物
EP2826778B1 (en) 2006-11-03 2017-09-20 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US20100075966A1 (en) 2006-11-27 2010-03-25 Novartis Ag Substituted Dihydroimidazoles and their Use in the Treatment of Tumors
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
AU2008251504B2 (en) 2007-05-09 2013-07-18 Vertex Pharmaceuticals Incorporated Modulators of CFTR
CN101687883B (zh) 2007-05-25 2012-05-23 沃泰克斯药物股份有限公司 囊性纤维化跨膜传导调节因子的调节剂
WO2009023509A2 (en) 2007-08-09 2009-02-19 Vertex Pharmaceuticals Incorporated Therapeutic combinations useful in treating cftr related diseases
WO2009038913A2 (en) 2007-08-24 2009-03-26 Vertex Pharmaceuticals Incorporated Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
DE102007042754A1 (de) 2007-09-07 2009-03-12 Bayer Healthcare Ag Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
JP2010540417A (ja) 2007-09-14 2010-12-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
WO2009036412A1 (en) 2007-09-14 2009-03-19 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
FR2921657A1 (fr) 2007-09-28 2009-04-03 Sanofi Aventis Sa Derives de nicotinamide, leur preparation et leur application en therapeutique
SI2217572T1 (sl) 2007-11-16 2014-05-30 Vertex Pharmaceuticals Incorporated Izokinolinski modulatorji prenaĺ alcev z atp-vezavno kaseto
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
PL2225230T3 (pl) 2007-12-07 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
JP2011506331A (ja) 2007-12-07 2011-03-03 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の処方物
PL2231606T3 (pl) 2007-12-07 2013-07-31 Vertex Pharma Sposoby wytwarzania kwasów cykloalkilokarboksyamidopirydynobenzoesowych
ES2422741T3 (es) 2007-12-13 2013-09-13 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2009108657A2 (en) 2008-02-28 2009-09-03 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
ES2442945T3 (es) 2008-03-31 2014-02-14 Vertex Pharmaceuticals Inc. Derivados de piridilo como moduladores del CFTR
GB0813709D0 (en) 2008-07-26 2008-09-03 Univ Dundee Method and product
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
DK2328618T3 (en) 2008-08-13 2018-02-19 Vertex Pharma PHARMACEUTICAL COMPOSITION OF N- [2,4-BIS (1,1-DIMETHYLETHYL) -5-HYDROXYPHENYL] -1,4-DIHYDRO-4-OXOQUINOLIN-3-CARBOXAMIDE AND ADMINISTRATION THEREOF
MX2011003249A (es) 2008-09-29 2011-05-19 Vertex Pharma Unidades de dosificacion del acido 3-(6-(1-(2,2-difluorobenzo[d][1 ,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoi co.
AR074060A1 (es) 2008-10-23 2010-12-22 Vertex Pharma Moduladores del regulador de conductancia transmembrana de la fibrosis quistica
CA2742042A1 (en) 2008-10-23 2010-04-29 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
DK2358680T3 (da) 2008-10-23 2013-06-24 Vertex Pharma Faste former af n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluormethyl)phenyl)-3-oxo-5-(trifluormethyl)-1,4-dihydroquinolin-3-carboxamid
US20110257223A1 (en) 2008-10-23 2011-10-20 Vertex Pharmaceuticals Incorporated Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
UA104876C2 (uk) 2008-11-06 2014-03-25 Вертекс Фармасьютікалз Інкорпорейтед Модулятори atф-зв'язувальних касетних транспортерів
KR20160013251A (ko) 2008-11-06 2016-02-03 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ-결합 카세트 수송자의 조절자
US8367660B2 (en) 2008-12-30 2013-02-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
NZ595151A (en) 2009-03-20 2013-11-29 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
SG193156A1 (en) 2009-03-20 2013-09-30 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
EP2427166B1 (en) 2009-05-07 2013-10-16 Gea Pharma Systems Limited Tablet production module and method for continuous production of tablets
US8404865B2 (en) 2009-09-17 2013-03-26 Vertex Pharmaceuticals Process for preparing azabicyclic compounds
AU2010310449A1 (en) 2009-10-22 2012-05-03 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
CN102648182A (zh) 2009-10-23 2012-08-22 沃泰克斯药物股份有限公司 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
BR112012009584A2 (pt) 2009-10-23 2019-09-24 Vertex Pharma formas sólidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2-(trifluorometil)fenil)-4-oxo-5-(trifluorometil)-1,4-di-hidroquinolina-3-carboxamida
EP3037415A1 (en) 2010-03-19 2016-06-29 Vertex Pharmaceuticals Inc. Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
EP4253381A3 (en) 2010-03-25 2023-11-01 Vertex Pharmaceuticals Incorporated Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]d ioxol-5-yl)-n-(1-(2,3-dihydroxyp ropyl)-6-fluoro-2-(1-hydroxy- 2-methylpropan-2-yl)-1h-indol- 5-yl) cyclopropanecarboxamide
DK2555754T3 (en) 2010-04-07 2016-04-18 Vertex Pharma Solid forms of 3- (6- (1- (2,2-difluoro-benzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) -benzoic acid
AU2011237601B2 (en) 2010-04-07 2015-08-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
AU2011242454A1 (en) 2010-04-22 2012-11-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
EP3138563A1 (en) 2010-04-22 2017-03-08 Vertex Pharmaceuticals Inc. Pharmaceutical compositions and administrations thereof
WO2011133956A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
ES2608474T3 (es) 2010-04-22 2017-04-11 Vertex Pharmaceuticals Incorporated Proceso de producción de compuestos indol cycloalkylcarboxamido
AR081920A1 (es) 2010-05-20 2012-10-31 Vertex Pharma Procesos de produccion de moduladores del regulador de conductancia transmembrana de fibrosis quistica
WO2011146901A1 (en) 2010-05-20 2011-11-24 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
JP2013536231A (ja) 2010-08-23 2013-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド （ｒ）−１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）−ｎ−（１−（２，３−ジヒドロキシプロピル）−６−フルオロ−２−（１−ヒドロキシ−２−メチルプロパン−２−イル）−１ｈ−インドール−５−イル）シクロプロパンカルボキサミドを含む医薬組成物およびその投与
EP2608775A2 (en) 2010-08-27 2013-07-03 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
WO2013067410A1 (en) 2011-11-02 2013-05-10 Vertex Pharmaceuticals Incorporated Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - ca rboxamide) for treating cftr mediated diseases
US20140127901A1 (en) 2012-11-08 2014-05-08 Taiwan Semiconductor Manufacturing Company, Ltd. Low-k damage free integration scheme for copper interconnects
US9254291B2 (en) 2011-11-08 2016-02-09 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
PL2806859T3 (pl) 2012-01-25 2019-11-29 Vertex Pharma Formulacje kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5- ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
US20130224293A1 (en) 2012-02-27 2013-08-29 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CA2874851A1 (en) 2012-06-08 2013-12-12 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cftr-mediated disorders
EP2872122A1 (en) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
UA117464C2 (uk) 2012-11-02 2018-08-10 Вертекс Фармасьютікалз Інкорпорейтед Фармацевтична композиція для лікування захворювання, опосередкованого трансмембранним регулятором провідності муковісцидозу cftr
US20140221424A1 (en) 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
LT3131582T (lt) 2014-04-15 2018-10-25 Vertex Pharmaceuticals Incorporated Farmacinės kompozicijos, skirtos cistinės fibrozės transmembraninio laidumo reguliatorių sukeltų ligų gydymui
RU2020134082A (ru) 2014-10-06 2020-11-27 Вертекс Фармасьютикалз Инкорпорейтед Модуляторы регулятора трансмембранной проводимости при муковисцидозе
MX370450B (es) 2014-10-07 2019-12-13 Vertex Pharma Co-cristales de moduladores de regulador de conductancia de transmembrana en fibrosis quistica.
MA41031A (fr) 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
WO2016086136A1 (en) 2014-11-26 2016-06-02 Catabasis Pharmaceuticals, Inc. Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders
WO2016087665A2 (en) 2014-12-05 2016-06-09 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating cystic fibrosis
WO2016123028A1 (en) 2015-01-26 2016-08-04 Rigel Pharmaceuticals, Inc. Tetrazolones as carboxylic acid bioisosteres
TWI730959B (zh) 2015-05-19 2021-06-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺

Also Published As

Publication number Publication date
PL2231606T3 (pl) 2013-07-31
DK2639224T3 (en) 2016-10-17
US8592602B2 (en) 2013-11-26
EP2639222A1 (en) 2013-09-18
PT2639223T (pt) 2017-05-08
US20160200712A1 (en) 2016-07-14
IL226411A0 (en) 2013-06-27
RS55360B1 (sr) 2017-03-31
JP2015044854A (ja) 2015-03-12
WO2009076142A2 (en) 2009-06-18
SI2639223T1 (sl) 2017-07-31
EP2639223A1 (en) 2013-09-18
HRP20170851T1 (hr) 2017-08-25
EP2231606A2 (en) 2010-09-29
HRP20130418T1 (en) 2013-06-30
DK2231606T3 (da) 2013-05-13
KR20150066608A (ko) 2015-06-16
IL206205A (en) 2014-04-30
JP2011506332A (ja) 2011-03-03
RS55298B1 (sr) 2017-03-31
ES2604178T3 (es) 2017-03-03
HK1199019A1 (en) 2015-06-19
HUE032268T2 (en) 2017-09-28
IL206205A0 (en) 2010-12-30
CA2707494A1 (en) 2009-06-18
BRPI0820902A2 (pt) 2015-06-23
PL2639223T3 (pl) 2017-09-29
KR101674404B1 (ko) 2016-11-09
CA3147290A1 (en) 2009-06-18
AU2008335440B2 (en) 2013-11-07
WO2009076142A3 (en) 2009-09-24
SI2231606T1 (sl) 2013-06-28
MX2010006183A (es) 2010-10-15
RS56083B1 (sr) 2017-10-31
CN101910134B (zh) 2014-03-19
JP2016026233A (ja) 2016-02-12
JP2014043469A (ja) 2014-03-13
IL226410A (en) 2014-07-31
HUE029775T2 (en) 2017-04-28
EP2639222B1 (en) 2016-08-31
HK1146820A1 (en) 2011-07-15
US9776968B2 (en) 2017-10-03
IL226412A0 (en) 2013-06-27
IL226411A (en) 2014-11-30
LT2639223T (lt) 2017-06-26
CA2989620C (en) 2022-05-03
CL2010000631A1 (es) 2011-04-01
CA2707494C (en) 2018-04-24
ES2406940T3 (es) 2013-06-10
RS52759B (en) 2013-08-30
MX364936B (es) 2019-05-15
CA2989620A1 (en) 2009-06-18
US20140121379A1 (en) 2014-05-01
MX365732B (es) 2019-06-12
KR101612009B1 (ko) 2016-04-12
CN101910134A (zh) 2010-12-08
PT2639222T (pt) 2016-11-01
JP5702149B2 (ja) 2015-04-15
EP2231606B1 (en) 2013-02-13
EP2639223B1 (en) 2017-03-29
HRP20161572T1 (hr) 2016-12-30
SI2639222T1 (sl) 2016-12-30
US20090176989A1 (en) 2009-07-09
CY1118310T1 (el) 2017-06-28
CN103864678B (zh) 2016-05-11
US8124781B2 (en) 2012-02-28
KR20100101132A (ko) 2010-09-16
EP2639224A1 (en) 2013-09-18
US20120190856A1 (en) 2012-07-26
ES2625957T3 (es) 2017-07-21
IL226412A (en) 2014-07-31
NZ612635A (en) 2015-06-26
HUE031871T2 (en) 2017-08-28
MX364935B (es) 2019-05-15
LT2639222T (lt) 2016-12-12
CY1118332T1 (el) 2017-06-28
HRP20161543T1 (hr) 2017-01-13
PL2639222T3 (pl) 2017-02-28
KR20160043147A (ko) 2016-04-20
SI2639224T1 (sl) 2016-12-30
JP5797726B2 (ja) 2015-10-21
EA201070700A1 (ru) 2011-06-30
DK2639223T3 (en) 2017-06-19
EP2639224B1 (en) 2016-08-24
DK2639222T3 (en) 2016-10-03
US20170158676A9 (en) 2017-06-08
US9321725B2 (en) 2016-04-26
NZ585794A (en) 2012-05-25
ES2604555T3 (es) 2017-03-07
IL226410A0 (en) 2013-06-27
CN103864678A (zh) 2014-06-18
PT2231606E (pt) 2013-05-17
LT2639224T (lt) 2016-10-25
ZA201003624B (en) 2011-08-31
PT2639224T (pt) 2016-12-01
PL2639224T3 (pl) 2017-02-28
CY1118992T1 (el) 2018-01-10
AU2008335440A1 (en) 2009-06-18
NZ599684A (en) 2013-08-30

Similar Documents

Publication Publication Date Title
CY1118332T1 (el) Μεθοδοι παραγωγης κυκλοαλκυλκαρβοξamιδο-πυριδιno βενζοϊκων οξεων
CY1111045T1 (el) Μεθοδος παραγωγης ενος παραγωγου βενζιμιδαζολιου
EA201200537A1 (ru) Способ получения глюкопиранозил-замещенных производных бензилбензола
CY1110411T1 (el) Μεθοδος για την παραγωγη 3-οξο-πρεγν-4-ενο-21,17-καρβολακτονων μεσω της οξειδωσης 17-(3-υδροξυπροπυλο)-3,17-διυδροξυανδροστανιων ανευ μεταλλου
CY1115036T1 (el) Μεθοδος για παραγωγη χειραλικων 8-(3-αμινο-πιπεριδιν-1-υλο)-ξανθινων
MX344084B (es) Procedimiento para la síntesis regioselectiva de derivados de ácido 1-alquil-3-haloalquil-pirazol-4-carboxílico.
ATE427965T1 (de) Antikírper gegen 25-hydroxyvitamin d
BR112012011689B8 (pt) processo para a produção de etexilato de dabigatran e compostos intermediários
EA200702614A1 (ru) Способы получения 4-(бифенилил)азетидин-2-оналкилфосфиновых кислот
UA111142C2 (uk) Одержання заміщених похідних 2-фторакрилової кислоти
MX2009007436A (es) Derivados espirociclicos de acido tetronico.
EA201170168A1 (ru) Комплекс (минерал-аминокислота)-полисахарид
MY150280A (en) Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
CL2012000560A1 (es) Procedimiento de preparacion del compuesto intermediario acido 3-oxo-tetrahidrotiofeno-2-carboxilico, utiles en la preparacion de dihidrotienopirimidinas (divisional de la solicitud 3095-08).
MX362689B (es) Procedimiento de preparacion de derivados de acido 3,5-bis(fluoroalquil)pirazol-4-carboxilico y 3,5-bis(fluoroalquil) pirazoles.
NZ601805A (en) Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same
EA201000379A1 (ru) Способ получения 2-сульфинил-1н-бензоимидазолов
TW200738704A (en) New process for the production of tiotropium salts
EA200801893A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве ингибиторов воспаления
EA200870038A1 (ru) Способ получения аминов
EA201390336A1 (ru) Способ получения промежуточного соединения для синтеза лекарственного средства
ATE526312T1 (de) Verfahren zur herstellung von reinen 4- pyrrolidinophenylbenzyletherderivaten als maob- inhibitoren
ATE466003T1 (de) Herstellung von 2-aminothiazol-5- carbonsäurederivaten
BR112012008017A2 (pt) 1,2,4-triazina, utilização de uma 1,2,4-triazina e processo de preparação de uma 1,2,4-triazina
CY1111873T1 (el) Νεα μεθοδος παραλαβης της κρυσταλλικης μορφης v της αγομελατινης